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Background
Tuberculosis lymphadenopathy is the most common
form of extrapulmonary tuberculosis. The aim of the
present study is to detect the duration of treatment
required in patients with cervical lymphadenopathy.
Methods
The patients attending the Department of Pulmonary
Medicine OPD with cervical lymphadenopathy were
screened. Detailed history, clinical examination, USG
neck, FNAC, Mantoux test, biopsy, and chest X ray frontal
view were performed and anti tuberculosis treatment
initiated.
Results
Total patients examined: 117, in the age group 10-70
years (mean age 40). Females affected – 89 (76.07%),
Males - 28 (23.93%). Most common age group affected
(M/F): 15-20 years: 37 (31.63%) patients. Biopsy was
done in 73 patients (62.39%). Patients received Category-
1ATT under RNTCP. After 6 months of therapy, 22
patients (18.81%) stopped treatment in view of non-
palpable mass. Out of remaining 95 patients (81.19%),
14 patients’ (11.96%) lymph node size increased with
slow regression, 17 patients’ (14.52%) liquefaction and
repeated aspiration was done, 57 patients’ (48.72%)
lymph node size showed regression less than 50%,
7 patients (5.98%) came up with new group of lymph
nodes with size gradually increased. For all 95 patients,
therapy was extended (continuation phase) for 2-3
months. 7 patients received ATT for 12 months.
Conclusion
Extrapulmonary tuberculosis like tuberculous lymphade-
nopathy is benefited with extension of anti tuberculosis
treatment.
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